Healthcare Analysts, along with Dr. Wharton, a cardiologist from North Shore University Hospital, discuss the market opportunity in treating Hypertrophic Cardiomyopathy (HCM), with a focus on Camzyos (Mavacamten) by Bristol Myers Squibb (BMY), as well as the Aficamten program by Cytokinetics (CYTK) and its Phase 3 Trial (SEQUOIA) on an Analyst/Industry conference call to be held on November 20 at 1 pm.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BMY:
- Bristol Myers Squibb (NYSE:BMY) Falls after FDA Delays Action on Cancer Therapy
- LianBio price target lowered to $5 from $6 at BofA
- Truist biotech analyst to hold an analyst/industry conference call
- Homology Medicines, Q32 Bio enter all-stock merger agreement
- Bristol Myers announces FDA approves Augtyro in NSCLC treatment